Effects of prostaglandins and COX-inhibiting drugs on skeletal muscle adaptations to exercise

Journal of Applied Physiology

Volumn 115, Issue 6, 2013, Pages 909-919

  Trappe, Todd A ^a   Liu, Sophia Z ^a  

^a BALL STATE UNIVERSITY   (United States)

Author keywords

Acetaminophen; Ibuprofen; PGE2; PGF2 ; Sarcopenia

Indexed keywords

IBUPROFEN; PARACETAMOL; PROSTAGLANDIN; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR;

ADAPTATION; ANIMAL; DRUG EFFECT; EXERCISE; HUMAN; PGF2Α; PHYSIOLOGY; REVIEW; SARCOPENIA; SIGNAL TRANSDUCTION; SKELETAL MUSCLE;

ACETAMINOPHEN; IBUPROFEN; PGE2; PGF2Α; SARCOPENIA;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; CYCLOOXYGENASE INHIBITORS; EXERCISE; HUMANS; MUSCLE, SKELETAL; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; SIGNAL TRANSDUCTION;

EID: 84884215334     PISSN: 87507587     EISSN: 15221601     Source Type: Journal    
DOI: 10.1152/japplphysiol.00061.2013     Document Type: Review

References (142)

1. Abramovitz M, Boie Y, Nguyen T, Rushmore TH, Bayne MA, Metters KM, Slipetz DM, Grygorczyk R. Cloning and expression of a cDNA for the human prostanoid FP receptor. J Biol Chem 269: 2632-2636, 1994.
2. Alkner BA, Tesch PA. Knee extensor and plantar flexor muscle size and function following 90 days of bed rest with or without resistance exercise. Eur J Appl Physiol 93: 294-305, 2004.
3. Alvarez P, Levine JD, Green PG. Eccentric exercise induces chronic alterations in musculoskeletal nociception in the rat. Eur J Neurosci 32: 819-825, 2010.
4. Aronoff DM. Aspirin and Reye's syndrome: discovery of aspirin and paracetamol. Drug Saf 25: 751, 2002.
5. Baracos V, Rodemann HP, Dinarello CA, Goldberg AL. Stimulation of muscle protein degradation and prostaglandin E2 release by leukocytic pyrogen (interleukin-1). A mechanism for the increased degradation of muscle proteins during fever. N Engl J Med 308: 553-558, 1983.
6. Barbieri M, Ferrucci L, Ragno E, Corsi A, Bandinelli S, Bonafe M, Olivieri F, Giovagnetti S, Franceschi C, Guralnik JM, Paolisso G. Chronic inflammation and the effect of IGF-I on muscle strength and power in older persons. Am J Physiol Endocrinol Metab 284: E481-E487, 2003.
7. Barnett JG, Ellis S. Prostaglandin E2 and the regulation of protein degradation in skeletal muscle. Muscle Nerve 10: 556-559, 1987.
8. Bauman DR, Rudnick SI, Szewczuk LM, Jin Y, Gopishetty S, Penning TM. Development of nonsteroidal anti-inflammatory drug analogs and steroid carboxylates selective for human aldo-keto reductase isoforms: potential antineoplastic agents that work independently of cyclooxygenase isozymes. Mol Pharmacol 67: 60-68, 2005.
9. Bergstrom S, Duner H, von EU, Pernow B, Sjovall J. Observations on the effects of infusion of prostaglandin E in man. Acta Physiol Scand 45: 145-151, 1959.
10. Bergström SK. Nobel Lecture: The Prostaglandins: from the Laboratory to the Clinic (Online). Nobelprize.org. http://www.nobelprize.org/nobel-prizes/ medicine/laureates/1982/bergstrom-lecture.html [8 Dec 1982].
11. Berlin T, Cronestrand R, Nowak J, Sonnenfeld T, Wennmalm A. Conversion of arachidonic acid to prostaglandins in homogenates of human skeletal muscle and kidney. Acta Physiol Scand 106: 441-445, 1979.
12. Bodell PW, Kodesh E, Haddad F, Zaldivar FP, Cooper DM, Adams GR. Skeletal muscle growth in young rats is inhibited by chronic exposure to IL-6 but preserved by concurrent voluntary endurance exercise. J Appl Physiol 106: 443-453, 2009.
13. Bondesen BA, Mills ST, Kegley KM, Pavlath GK. The COX-2 pathway is essential during early stages of skeletal muscle regeneration. Am J Physiol Cell Physiol 287: C475-C483, 2004.
14. Bondesen BA, Mills ST, Pavlath GK. The COX-2 pathway regulates growth of atrophied muscle via multiple mechanisms. Am J Physiol Cell Physiol 290: C1651-C1659, 2006.
15. Boushel R, Langberg H, Gemmer C, Olesen J, Crameri R, Scheede C, Sander M, Kjaer M. Combined inhibition of nitric oxide and prostaglandins reduces human skeletal muscle blood flow during exercise. J Physiol 543: 691-698, 2002.
16. Boutaud O, Aronoff DM, Richardson JH, Marnett LJ, Oates JA. Determinants of the cellular specificity of acetaminophen as an inhibitor of prostaglandin H2 synthases. Proc Natl Acad Sci USA 99: 7130-7135, 2002.
17. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD. Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 41: 661-690, 2001.
18. Burd NA, Dickinson JM, Lemoine JK, Carroll CC, Sullivan BE, Haus JM, Jemiolo B, Trappe SW, Hughes GM, Sanders CE Jr, Trappe TA. Effect of a cyclooxygenase-2 inhibitor on postexercise muscle protein synthesis in humans. Am J Physiol Endocrinol Metab 298: E354-E361, 2010.
19. Burke JE, Dennis EA. Phospholipase A2 biochemistry. Cardiovasc Drugs Ther 23: 49-59, 2009.
20. Cai D, Frantz JD, Tawa NE Jr, Melendez PA, Oh BC, Lidov HG, Hasselgren PO, Frontera WR, Lee J, Glass DJ, Shoelson SE. IKKbeta/ NF-kappaB activation causes severe muscle wasting in mice. Cell 119: 285-298, 2004.
21. Caldow MK, Cameron-Smith D, Levinger P, McKenna MJ, Levinger I. Inflammatory markers in skeletal muscle of older adults. Eur J Appl Physiol 113: 509-517, 2013.
22. Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, Simmons DL. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 99: 13926-13931, 2002.
23. Chesley A, MacDougall JD, Tarnopolsky MA, Atkinson SA, Smith K. Changes in human muscle protein synthesis after resistance exercise. J Appl Physiol 73: 1383-1388, 1992.
24. Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 104: 413-421, 1998.
25. de Gonzalo-Calvo D, de Luxan-Delgado B, Rodriguez-Gonzalez S, Garcia-Macia M, Suarez FM, Solano JJ, Rodriguez-Colunga MJ, Coto-Montes A. Interleukin 6, soluble tumor necrosis factor receptor I and red blood cell distribution width as biological markers of functional dependence in an elderly population: a translational approach. Cytokine 58: 193-198, 2012.
26. Dennis RA, Zhu H, Kortebein PM, Bush HM, Harvey JF, Sullivan DH, Peterson CA. Muscle expression of genes associated with inflammation, growth, and remodeling is strongly correlated in older adults with resistance training outcomes. Physiol Genomics 38: 169-175, 2009.
27. Dupouy VM, Ferre PJ, Uro-Coste E, Lefebvre HP. Time course of COX-1 and COX-2 expression during ischemia-reperfusion in rat skeletal muscle. J Appl Physiol 100: 233-239, 2006.
28. Ferrucci L, Harris TB, Guralnik JM, Tracy RP, Corti MC, Cohen HJ, Penninx B, Pahor M, Wallace R, Havlik RJ. Serum IL-6 level and the development of disability in older persons. J Am Geriatr Soc 47: 639-646, 1999.
29. Flodgren GM, Crenshaw AG, Alfredson H, Fahlstrom M, Hellstrom FB, Bronemo L, Djupsjobacka M. Glutamate and prostaglandin E2 in the trapezius muscle of female subjects with chronic muscle pain and controls determined by microdialysis. Eur J Pain 9: 511-515, 2005.
30. Flodgren GM, Hellstrom FB, Fahlstrom M, Crenshaw AG. Effects of 30 versus 60 min of low-load work on intramuscular lactate, pyruvate, glutamate, prostaglandin E(2) and oxygenation in the trapezius muscle of healthy females. Eur J Appl Physiol 97: 557-565, 2006.
31. Flower RJ, Vane JR. Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol). Nature 240: 410-411, 1972.
32. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294: 1871-1875, 2001.
33. Gibson JN, Poyser NL, Morrison WL, Scrimgeour CM, Rennie MJ. Muscle protein synthesis in patients with rheumatoid arthritis: effect of chronic corticosteroid therapy on prostaglandin F2 availability. Eur J Clin Invest 21: 406-412, 1991.
34. Goldberg AL, Baracos V, Rodemann P, Waxman L, Dinarello C. Control of protein degradation in muscle by prostaglandins, Ca2+, and leukocytic pyrogen (interleukin 1). Fed Proc 43: 1301-1306, 1984.
35. Goldberg AL, Kettelhut IC, Furuno K, Fagan JM, Baracos V. Activation of protein breakdown and prostaglandin E2 production in rat skeletal muscle in fever is signaled by a macrophage product distinct from interleukin 1 or other known monokines. J Clin Invest 81: 1378-1383, 1988.
36. Greiwe JS, Cheng B, Rubin DC, Yarasheski KE, Semenkovich CF. Resistance exercise decreases skeletal muscle tumor necrosis factor alpha in frail elderly humans. FASEB J 15: 475-482, 2001.
37. Haddad F, Zaldivar F, Cooper DM, Adams GR. IL-6-induced skeletal muscle atrophy. J Appl Physiol 98: 911-917, 2005.
38. Haq S, Kilter H, Michael A, Tao J, O'Leary E, Sun XM, Walters B, Bhattacharya K, Chen X, Cui L, Andreucci M, Rosenzweig A, Guerrero JL, Patten R, Liao R, Molkentin J, Picard M, Bonventre JV, Force T. Deletion of cytosolic phospholipase A2 promotes striated muscle growth. Nat Med 9: 944-951, 2003.
39. Hasselgren PO, Warner BW, Hummel RP 3rd, James JH, Ogle CK, Fischer JE. Further evidence that accelerated muscle protein breakdown during sepsis is not mediated by prostaglandin E2. Ann Surg 207: 399-403, 1988.
40. Hasselgren PO, Zamir O, James JH, Fischer JE. Prostaglandin E2 does not regulate total or myofibrillar protein breakdown in incubated skeletal muscle from normal or septic rats. Biochem J 270: 45-50, 1990.
41. Herbaczynska-Cedro K, Staszewska-Barczak J. Proceedings: muscular work and prostaglandin release. Br J Pharmacol 52: 454P-455P, 1974.
42. Herbaczynska-Cedro K, Staszewska-Barczak J, Janczewska H. Muscular work and the release of prostaglandin-like substances. Cardiovasc Res 10: 413-420, 1976.
43. Herbaczynska-Cedro K, Staszewska-Barczak J, Janczewska H. The release of prostaglandin-like substances during reactive and functional hyperemia in the hind leg of the dog. Pol J Pharmacol Pharm 26: 167-170, 1974.
44. Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA 89: 7384-7388, 1992.
45. Höffner L, Nielsen JJ, Langberg H, Hellsten Y. Exercise but not prostanoids enhance levels of vascular endothelial growth factor and other proliferative agents in human skeletal muscle interstitium. J Physiol 550: 217-225, 2003.
46. Jackson JR, Mula J, Kirby TJ, Fry CS, Lee JD, Ubele MF, Campbell KS, McCarthy JJ, Peterson CA, Dupont-Versteegden EE. Satellite cell depletion does not inhibit adult skeletal muscle regrowth following unloading-induced atrophy. Am J Physiol Cell Physiol 303: C854-C861, 2012.
47. Janczewska H, Herbaczynska-Cedro K. Effect of indomethacin on vascular responses to vasoactive agents in working skeletal muscles in the dog. Pol J Pharmacol Pharm 26: 159-166, 1974.
48. Jankowski CM, Gozansky WS, Maclean PS, Shulman B, Wolfe P, Schwartz RS, Kohrt WM. N-Acetyl-4-aminophenol and musculoskeletal adaptations to resistance exercise training. Eur J Appl Physiol 113: 1127-1136, 2013.
49. Karamouzis M, Karamouzis I, Vamvakoudis E, Ampatzidis G, Christoulas K, Angelopoulou N, Mandroukas K. The response of muscle interstitial prostaglandin E2 (PGE2), prostacyclin I2 (PGI2) and thromboxane A2 (TXA2) levels during incremental dynamic exercise in humans determined by in vivo microdialysis. Prostaglandins Leukot Essent Fatty Acids 64: 259-263, 2001.
50. Karamouzis M, Langberg H, Skovgaard D, Bulow J, Kjaer M, Saltin B. In situ microdialysis of intramuscular prostaglandin and thromboxane in contracting skeletal muscle in humans. Acta Physiol Scand 171: 71-76, 2001.
51. Karim SM, Sandler M, Williams ED. Distribution of prostaglandins in human tissues. Br J Pharmacol Chemother 31: 340-344, 1967.
52. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 287: 337-344, 2002.
53. KEGG (Kyoto Encyclopedia of Genes and Genomes). Arachidonic Acid Metabolism-Reference Pathway (Online). Kyoto University, Kyoto, Japan. http://www.genome.jp/kegg/pathway/map/map00590.html [8 Feb 2013].
54. Kilbom A, Wennmalm A. Endogenous prostaglandins as local regulators of blood flow in man: effect of indomethacin on reactive and functional hyperaemia. J Physiol 257: 109-121, 1976.
55. Kreiner F, Galbo H. Elevated muscle interstitial levels of pain-inducing substances in symptomatic muscles in patients with polymyalgia rheumatica. Pain 152: 1127-1132, 2011.
56. Krentz JR, Quest B, Farthing JP, Quest DW, Chilibeck PD. The effects of ibuprofen on muscle hypertrophy, strength, and soreness during resistance training. Appl Physiol Nutr Metab 33: 470-475, 2008.
57. Louis E, Raue U, Yang Y, Jemiolo B, Trappe S. Time course of proteolytic, cytokine, and myostatin gene expression after acute exercise in human skeletal muscle. J Appl Physiol 103: 1744-1751, 2007.
58. MacDougall JD, Gibala MJ, Tarnopolsky MA, MacDonald JR, Interisano SA, Yarasheski KE. The time course for elevated muscle protein synthesis following heavy resistance exercise. Can J Appl Physiol 20: 480-486, 1995.
59. Machida M, Takemasa T. Ibuprofen administration during endurance training cancels running-distance-dependent adaptations of skeletal muscle in mice. J Physiol Pharmacol 61: 559-563, 2010.
60. Mackey AL, Holm L, Reitelseder S, Pedersen TG, Doessing S, Kadi F, Kjaer M. Myogenic response of human skeletal muscle to 12 weeks of resistance training at light loading intensity. Scand J Med Sci Sports 21: 773-782, 2011.
61. Mackey AL, Kjaer M, Dandanell S, Mikkelsen KH, Holm L, Dossing S, Kadi F, Koskinen SO, Jensen CH, Schroder HD, Langberg H. The influence of anti-inflammatory medication on exercise-induced myogenic precursor cell responses in humans. J Appl Physiol 103: 425-431, 2007.
62. Markworth JF, Cameron-Smith D. Prostaglandin F2; stimulates PI3K/ERK/mTOR signaling and skeletal myotube hypertrophy. Am J Physiol Cell Physiol 300: C671-C682, 2011.
63. McCarthy JJ, Esser KA. Counterpoint: satellite cell addition is not obligatory for skeletal muscle hypertrophy. J Appl Physiol 103: 1100-1102, 2007.
64. McMillan DN, Reeds PJ, Lobley GE, Palmer RM. Changes in protein turnover in hypertrophying plantaris muscles of rats: effect of fenbufen- an inhibitor of prostaglandin synthesis. Prostaglandins 34: 841-852, 1987.
65. McNurlan MA, McHardy KC, Broom J, Milne E, Fearns LM, Reeds PJ, Garlick PJ. The effect of indomethacin on the response of protein synthesis to feeding in rats and man. Clin Sci (Lond) 73: 69-75, 1987.
66. Mense S. Algesic agents exciting muscle nociceptors. Exp Brain Res 196: 89-100, 2009.
67. Mikkelsen UR, Helmark IC, Kjaer M, Langberg H. Prostaglandin synthesis can be inhibited locally by infusion of NSAIDS through microdialysis catheters in human skeletal muscle. J Appl Physiol 104: 534-537, 2008.
68. Mikkelsen UR, Langberg H, Helmark IC, Skovgaard D, Andersen LL, Kjaer M, Mackey AL. Local NSAID infusion inhibits satellite cell proliferation in human skeletal muscle after eccentric exercise. J Appl Physiol 107: 1600-1611, 2009.
69. Mikkelsen UR, Schjerling P, Helmark IC, Reitelseder S, Holm L, Skovgaard D, Langberg H, Kjaer M, Heinemeier KM. Local NSAID infusion does not affect protein synthesis and gene expression in human muscle after eccentric exercise. Scand J Med Sci Sports 21: 630-644, 2011.
70. Murakami M, Nakatani Y, Tanioka T, Kudo I. Prostaglandin E synthase. Prostaglandins Other Lipid Mediat 68-69: 383-399, 2002.
71. Nair KS. Muscle protein turnover: methodological issues and the effect of aging. J Gerontol A Biol Sci Med Sci 50 Spec No: 107-112, 1995.
72. Narumiya S, FitzGerald GA. Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest 108: 25-30, 2001.
73. Novak ML, Billich W, Smith SM, Sukhija KB, McLoughlin TJ, Hornberger TA, Koh TJ. COX-2 inhibitor reduces skeletal muscle hypertrophy in mice. Am J Physiol Regul Integr Comp Physiol 296: R1132-R1139, 2009.
74. Nowak J, Bohman SO, Alster P, Berlin T, Cronestrand R, Sonnenfeld T. Biosynthesis of prostaglandins in microsomes of human skeletal muscle and kidney. Prostaglandins Leukot Med 11: 269-279, 1983.
75. Nowak J, Wennmalm A. Effect of exercise on human arterial and regional venous plasma concentrations of prostaglandin E. Prostaglandins Med 1: 489-497, 1978.
76. O'Connor RS, Pavlath GK. Point:counterpoint: satellite cell addition is/is not obligatory for skeletal muscle hypertrophy. J Appl Physiol 103: 1099-1100, 2007.
77. Palmer RM. Prostaglandins and the control of muscle protein synthesis and degradation. Prostaglandins Leukot Essent Fatty Acids 39: 95-104, 1990.
78. Palmer RM, Reeds PJ, Atkinson T, Smith RH. The influence of changes in tension on protein synthesis and prostaglandin release in isolated rabbit muscles. Biochem J 214: 1011-1014, 1983.
79. Paulsen G, Egner IM, Drange M, Langberg H, Benestad HB, Fjeld JG, Hallen J, Raastad T. A COX-2 inhibitor reduces muscle soreness, but does not influence recovery and adaptation after eccentric exercise. Scand J Med Sci Sports 20: e195-e207, 2010.
80. Peake J, Della Gatta P, Cameron-Smith D. Aging and its effects on inflammation in skeletal muscle at rest and following exercise-induced muscle injury. Am J Physiol Regul Integr Comp Physiol 298: R1485-R1495, 2010.
81. Petersen SG, Beyer N, Hansen M, Holm L, Aagaard P, Mackey AL, Kjaer M. Nonsteroidal anti-inflammatory drug or glucosamine reduced pain and improved muscle strength with resistance training in a randomized controlled trial of knee osteoarthritis patients. Arch Phys Med Rehabil 92: 1185-1193, 2011.
82. Petersen SG, Miller BF, Hansen M, Kjaer M, Holm L. Exercise and NSAIDs: effect on muscle protein synthesis in patients with knee osteoarthritis. Med Sci Sports Exerc 43: 425-431, 2011.
83. Petrella JK, Kim JS, Mayhew DL, Cross JM, Bamman MM. Potent myofiber hypertrophy during resistance training in humans is associated with satellite cell-mediated myonuclear addition: a cluster analysis. J Appl Physiol 104: 1736-1742, 2008.
84. Phillips SM, Tipton KD, Aarsland A, Wolf SE, Wolfe RR. Mixed muscle protein synthesis and breakdown after resistance exercise in humans. Am J Physiol Endocrinol Metab 273: E99-E107, 1997.
85. Piper PJ, Vane JR, Wyllie JH. Inactivation of prostaglandins by the lungs. Nature 225: 600-604, 1970.
86. Qin N, Zhang SP, Reitz TL, Mei JM, Flores CM. Cloning, expression and functional characterization of human COX-1 splicing variants: evidence for intron 1 retention. J Pharmacol Exp Ther 315: 1298-1305, 2005.
87. Rabuel C, Renaud E, Brealey D, Ratajczak P, Damy T, Alves A, Habib A, Singer M, Payen D, Mebazaa A. Human septic myopathy: induction of cyclooxygenase, heme oxygenase and activation of the ubiquitin proteolytic pathway. Anesthesiology 101: 583-590, 2004.
88. Raue U, Slivka D, Jemiolo B, Hollon C, Trappe S. Proteolytic gene expression differs at rest and after resistance exercise between young and old women. J Gerontol 62: 1407-1412, 2007.
89. Raue U, Trappe TA, Estrem ST, Qian HR, Helvering LM, Smith RC, Trappe S. Transcriptome signature of resistance exercise adaptations: mixed muscle and fiber type specific profiles in young and old adults. J Appl Physiol 112: 1625-1636, 2012.
90. Reeds PJ, Palmer RM. The possible involvement of prostaglandin F2 in the stimulation of muscle protein synthesis by insulin. Biochem Biophys Res Commun 116: 1084-1090, 1983.
91. Reid CM, Storey E, Wong TY, Woods R, Tonkin A, Wang JJ, Kam A, Janke A, Essex R, Abhayaratna WP, Budge MM. Aspirin for the prevention of cognitive decline in the elderly: rationale and design of a neuro-vascular imaging study (ENVIS-ion). BMC Neurol 12: 3, 2012.
92. Rieu I, Magne H, Savary-Auzeloux I, Averous J, Bos C, Peyron MA, Combaret L, Dardevet D. Reduction of low grade inflammation restores blunting of postprandial muscle anabolism and limits sarcopenia in old rats. J Physiol 587: 5483-5492, 2009.
93. Rodemann HP, Goldberg AL. Arachidonic acid, prostaglandin E2 and F2 influence rates of protein turnover in skeletal and cardiac muscle. J Biol Chem 257: 1632-1638, 1982.
94. Rodemann HP, Waxman L, Goldberg AL. The stimulation of protein degradation in muscle by Ca2+ is mediated by prostaglandin E2 and does not require the calcium-activated protease. J Biol Chem 257: 8716-8723, 1982.
95. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377: 31-41, 2011.
96. Samuelsson B, Morgenstern R, Jakobsson PJ. Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol Rev 59: 207-224, 2007.
97. Samuelsson BI. Nobel Lecture: from Studies of Biochemical Mechanisms to Novel Biological Mediators: Prostaglandin Endoperoxides, Thromboxanes and Leukotrienes (Online). Nobelprize.org. http://www.nobelprize.org/nobel-prizes/ medicine/laureates/1982/samuelsson-lecture.html [8 Dec 1982].
98. Sandri M. Signaling in muscle atrophy and hypertrophy. Physiology 23: 160-170, 2008.
99. Schaap LA, Pluijm SM, Deeg DJ, Harris TB, Kritchevsky SB, Newman AB, Colbert LH, Pahor M, Rubin SM, Tylavsky FA, Visser M. Higher inflammatory marker levels in older persons: associations with 5-year change in muscle mass and muscle strength. J Gerontol 64: 1183-1189, 2009.
100. Schrage WG, Wilkins BW, Johnson CP, Eisenach JH, Limberg JK, Dietz NM, Curry TB, Joyner MJ. Roles of nitric oxide synthase and cyclooxygenase in leg vasodilation and oxygen consumption during prolonged low-intensity exercise in untrained humans. J Appl Physiol 109: 768-777, 2010.
101. Schwab JM, Beiter T, Linder JU, Laufer S, Schulz JE, Meyermann R, Schluesener HJ. COX-3-a virtual pain target in humans? FASEB J 17: 2174-2175, 2003.
102. Shen W, Li Y, Tang Y, Cummins J, Huard J. NS-398, a cyclooxygenase-2- specific inhibitor, delays skeletal muscle healing by decreasing regeneration and promoting fibrosis. Am J Pathol 167: 1105-1117, 2005.
103. Shen W, Li Y, Zhu J, Schwendener R, Huard J. Interaction between macrophages, TGF-beta1, and the COX-2 pathway during the inflammatory phase of skeletal muscle healing after injury. J Cell Physiol 214: 405-412, 2008.
104. Shen W, Prisk V, Li Y, Foster W, Huard J. Inhibited skeletal muscle healing in cyclooxygenase-2 gene-deficient mice: the role of PGE2 and PGF2. J Appl Physiol 101: 1215-1221, 2006.
105. Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 56: 387-437, 2004.
106. Smith RH, Palmer RM, Reeds PJ. Protein synthesis in isolated rabbit forelimb muscles. The possible role of metabolites of arachidonic acid in the response to intermittent stretching. Biochem J 214: 153-161, 1983.
107. Smith WL, Urade Y, Jakobsson PJ. Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis. Chem Rev 111: 5821-5865, 2011.
108. Smyth EM, Grosser T, Wang M, Yu Y, FitzGerald GA. Prostanoids in health and disease. J Lipid Res 50, Suppl: S423-S428, 2009.
109. Soltow QA, Betters JL, Sellman JE, Lira VA, Long JH, Criswell DS. Ibuprofen inhibits skeletal muscle hypertrophy in rats. Med Sci Sports Exerc 38: 840-846, 2006.
110. Standley RA, Liu SZ, Jemiolo B, Trappe SW, Trappe TA. Prostaglandin E2 induces transcription of skeletal muscle mass regulators interleukin-6 and muscle RING finger-1 in humans. Prostaglandins Leukot Essent Fatty Acids 88: 361-364, 2013.
111. Steensberg A, Keller C, Starkie RL, Osada T, Febbraio MA, Pedersen BK. IL-6 and TNF-alpha expression in, and release from, contracting human skeletal muscle. Am J Physiol Endocrinol Metab 283: E1272-E1278, 2002.
112. Sugimoto Y, Narumiya S. Prostaglandin E receptors. J Biol Chem 282: 11613-11617, 2007.
113. Templeton GH, Padalino M, Moss R. Influences of inactivity and indomethacin on soleus phosphatidylethanolamine and size. Prostaglandins 31: 545-559, 1986.
114. Tesch PA, Ekberg A, Lindquist DM, Trieschmann JT. Muscle hypertrophy following 5-week resistance training using a non-gravitydependent exercise system. Acta Physiol Scand 180: 89-98, 2004.
115. Tesch PA, Trieschmann JT, Ekberg A. Hypertrophy of chronically unloaded muscle subjected to resistance exercise. J Appl Physiol 96: 1451-1458, 2004.
116. Testa M, Rocca B, Spath L, Ranelletti FO, Petrucci G, Ciabattoni G, Naro F, Schiaffino S, Volpe M, Reggiani C. Expression and activity of cyclooxygenase isoforms in skeletal muscles and myocardium of humans and rodents. J Appl Physiol 103: 1412-1418, 2007.
117. Thalacker-Mercer AE, Dell'Italia LJ, Cui X, Cross JM, Bamman MM. Differential genomic responses in old vs. young humans despite similar levels of modest muscle damage after resistance loading. Physiol Genomics 40: 141-149, 2010.
118. Toth MJ, Matthews DE, Tracy RP, Previs MJ. Age-related differences in skeletal muscle protein synthesis: relation to markers of immune activation. Am J Physiol Endocrinol Metab 288: E883-E891, 2005.
119. Trappe S, Godard M, Gallagher P, Carroll C, Rowden G, Porter D. Resistance training improves single muscle fiber contractile function in older women. Am J Physiol Cell Physiol 281: C398-C406, 2001.
120. Trappe S, Trappe T, Gallagher P, Harber M, Alkner B, Tesch P. Human single muscle fibre function with 84 day bed-rest and resistance exercise. J Physiol 557: 501-513, 2004.
121. Trappe S, Williamson D, Godard M. Maintenance of whole muscle strength and size following resistance training in older men. J Gerontol 57: B138-B143, 2002.
122. Trappe S, Williamson D, Godard M, Porter D, Rowden G, Costill D. Effect of resistance training on single muscle fiber contractile function in older men. J Appl Physiol 89: 143-152, 2000.
123. Trappe T, Raue U, Williams R, Carrithers J, Hickner R. Effects of age and resistance exercise on skeletal muscle interstitial prostaglandin F2. Prostaglandins Leukot Essent Fatty Acids 74: 175-181, 2006.
124. Trappe T, Williams R, Carrithers J, Raue U, Esmarck B, Kjaer M, Hickner R. Influence of age and resistance exercise on human skeletal muscle proteolysis: a microdialysis approach. J Physiol 554: 803-813, 2004.
125. Trappe TA, Carroll CC, Dickinson JM, LeMoine JK, Haus JM, Sullivan BE, Lee JD, Jemiolo B, Weinheimer EM, Hollon CJ. Influence of acetaminophen and ibuprofen on skeletal muscle adaptations to resistance exercise in older adults. Am J Physiol Regul Integr Comp Physiol 300: R655-R662, 2011.
126. Trappe TA, Fluckey JD, White F, Lambert CP, Evans WJ. Skeletal muscle PGF2 and PGE2 in response to eccentric resistance exercise: influence of ibuprofen and acetaminophen. J Clin Endocrinol Metab 86: 5067-5070, 2001.
127. Trappe TA, Standley RA, Jemiolo B, Carroll CC, Trappe SW. Prostaglandin and myokine involvement in the cyclooxygenase-inhibiting drug enhancement of skeletal muscle adaptations to resistance exercise in older adults. Am J Physiol Regul Integr Comp Physiol 304: R198-R205, 2013.
128. Trappe TA, White F, Lambert CP, Cesar D, Hellerstein M, Evans WJ. Effect of ibuprofen and acetaminophen on postexercise muscle protein synthesis. Am J Physiol Endocrinol Metab 282: E551-E556, 2002.
129. United States Census Bureau. State & County QuickFacts (Online). U.S. Department of Commerce, Washington, DC. http://quickfacts.census. gov/qfd/states/00000.html [14 Mar 2013].
130. United States Preventative Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 150: 396-404, 2009.
131. van Hall G, Steensberg A, Fischer C, Keller C, Moller K, Moseley P, Pedersen BK. Interleukin-6 markedly decreases skeletal muscle protein turnover and increases nonmuscle amino acid utilization in healthy individuals. J Clin Endocrinol Metab 93: 2851-2858, 2008.
132. Vandenburgh HH, Hatfaludy S, Sohar I, Shansky J. Stretch-induced prostaglandins and protein turnover in cultured skeletal muscle. Am J Physiol Cell Physiol 259: C232-C240, 1990.
133. Vandenburgh HH, Shansky J, Karlisch P, Solerssi RL. Mechanical stimulation of skeletal muscle generates lipid-related second messengers by phospholipase activation. J Cell Physiol 155: 63-71, 1993.
134. Vandenburgh HH, Shansky J, Solerssi R, Chromiak J. Mechanical stimulation of skeletal muscle increases prostaglandin F2 production, cyclooxygenase activity, and cell growth by a pertussis toxin sensitive mechanism. J Cell Physiol 163: 285-294, 1995.
135. Vane JR. Nobel Lecture: Adventures and Excursions in Bioassay: the Stepping Stones to Prostacyclin (Online). Nobelprize.org. http://www.nobelprize. org/nobel-prizes/medicine/laureates/1982/vane-lecture.html [8 Dec 1982].
136. von Euler US. On the specific vaso-dilating and plain muscle stimulating substances from accessory genital glands in man and certain animals (prostaglandin and vesiglandin). J Physiol 88: 213-234, 1936.
137. Watanabe K. Prostaglandin F synthase. Prostaglandins Other Lipid Mediat 68-69: 401-407, 2002.
138. Weinheimer EM, Jemiolo B, Carroll CC, Harber MP, Haus JM, Burd NA, Lemoine JK, Trappe SW, Trappe TA. Resistance exercise and cyclooxygenase (COX) expression in human skeletal muscle: implications for COX-inhibiting drugs and protein synthesis. Am J Physiol Regul Integr Comp Physiol 292: R2241-R2248, 2007.
139. Wu M, Desai DH, Kakarla SK, Katta A, Paturi S, Gutta AK, Rice KM, Walker EM Jr, Blough ER. Acetaminophen prevents aging-associated hyperglycemia in aged rats: effect of aging-associated hyperactivation of p38-MAPK and ERK1/2. Diabetes Metab Res Rev 25: 279-286, 2009.
140. Wu M, Katta A, Gadde MK, Liu H, Kakarla SK, Fannin J, Paturi S, Arvapalli RK, Rice KM, Wang Y, Blough ER. Aging-associated dysfunction of Akt/protein kinase B: S-nitrosylation and acetaminophen intervention. PLoS One 4: e6430, 2009.
141. Yokoyama C, Tanabe T. Cloning of human gene encoding prostaglandin endoperoxide synthase and primary structure of the enzyme. Biochem Biophys Res Commun 165: 888-894, 1989.
142. Young MK, Bocek RM, Herrington PT, Beatty CH. Aging: effects on the prostaglandin production by skeletal muscle of male rhesus monkeys (Macaca mulatta). Mech Ageing Dev 16: 345-353, 1981.